Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: A meta-analysis

Digestive and Liver Disease

Volumn 46, Issue 3, 2014, Pages 219-226

  Yoshino, Takuya ^a,b   Nakase, Hiroshi ^a   Minami, Naoki ^a   Yamada, Satoshi ^a   Matsuura, Minoru ^a   Yazumi, Shujiro ^b   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Kitano Hospital   (Japan)

Author keywords

Corticosteroids; Granulocyte and monocyte adsorption apheresis; Ulcerative colitis

Indexed keywords

CORTICOSTEROID;

APHERESIS; ARTICLE; COMPARATIVE EFFECTIVENESS; DISEASE EXACERBATION; GRANULOCYTE; GRANULOCYTE AND MONOCYTE ADSORPTION APHERESIS; HEADACHE; HOT FLUSH; HUMAN; META ANALYSIS; MONOCYTE; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK ASSESSMENT; TREATMENT RESPONSE; ULCERATIVE COLITIS;

CORTICOSTEROIDS; GRANULOCYTE AND MONOCYTE ADSORPTION APHERESIS; ULCERATIVE COLITIS;

ADSORPTION; COLITIS, ULCERATIVE; GLUCOCORTICOIDS; GRANULOCYTES; HUMANS; LEUKAPHERESIS; MONOCYTES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84893777757     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.10.011     Document Type: Article

References (41)

1. Hanauer S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006, 12(Suppl. 1):S3-S9.
2. Williams C.N., Haber G., Aquino J.A. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories. Dig Dis Sci 1987, 32:71S-75S.
3. Sutherland L.R., Martin F., Bailey R.J., et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997, 112:1069-1077.
4. Hanauer S., Schwartz J., Robinson M., et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993, 88:1188-1197.
5. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 2:1041-1048.
6. Baron J.H., Connell A.M., Kanaghinis T.G., et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962, 2:441-443.
7. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
8. Yamamoto S., Nakase H., Mikami S., et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008, 28:589-597.
9. Yamamoto S., Nakase H., Matsuura M., et al. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol 2010, 25:886-891.
10. Sandborn W.J. Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology 1995, 109:1001-1003.
11. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260. [quiz 520].
12. Talar-Williams C., Sneller M.C. Complications of corticosteroid therapy. Eur Arch Otorhinolaryngol 1994, 251:131-136.
13. Mackey A.C., Green L., Liang L.C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:265-267.
14. Herrinton L.J., Liu L., Weng X., et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011, 106:2146-2153.
15. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
16. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
17. Papadakis K.A., Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000, 51:289-298.
18. Schreiber S., Nikolaus S., Hampe J., et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999, 353:459-461.
19. Tibble J.A., Sigthorsson G., Bridger S., et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119:15-22.
20. Saniabadi A.R., Hanai H., Takeuchi K., et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003, 7:48-59.
21. Hiraishi K., Takeda Y., Shiobara N., et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 2003, 7:334-340.
22. Shimoyama T., Sawada K., Hiwatashi N., et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001, 16:1-9.
23. Hanai H., Watanabe F., Yamada M., et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004, 70:36-44.
24. Hanai H., Iida T., Takeuchi K., et al. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 2008, 40:433-440.
25. Nakamura T., Kawagoe Y., Matsuda T., et al. Effect of granulocyte and monocyte adsorption apheresis on urinary albumin excretion and plasma endothelin-1 concentration in patients with active ulcerative colitis. Blood Purif 2004, 22:499-504.
26. Bresci G., Parisi G., Mazzoni A., et al. Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up. J Gastroenterol Hepatol 2008, 23:1678-1682.
27. Sands B.E., Sandborn W.J., Feagan B., et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008, 135:400-409.
28. Ricart E., Esteve M., Andreu M., et al. Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: a pilot, prospective, multicenter, randomized study. World J Gastroenterol 2007, 13:2193-2197.
29. Dignass A.U., Eriksson A., Kilander A., et al. Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther 2010, 31:1286-1295.
30. Sakuraba A., Sato T., Naganuma M., et al. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol 2008, 43:51-56.
31. Sakuraba A., Motoya S., Watanabe K., et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009, 104:2990-2995.
32. Yoshino T., Nakase H., Matsuura M., et al. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants. Digestion 2011, 84:3-9.
33. Yamamoto T., Umegae S., Matsumoto K. Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study. J Gastroenterol 2011, 46:1003-1009.
34. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
35. Yamamoto T., Umegae S., Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis 2010, 16:1905-1911.
36. Fukuchi T., Nakase H., Ito D., et al. Rapid induction of mucosal healing by intensive granulocyte and monocyte adsorptive aphaeresis in active ulcerative colitis patients without concomitant corticosteroid therapy. Aliment Pharmacol Ther 2011, 34:583-585.
37. Sinclair T.S., Brunt P.W., Mowat N.A. Nonspecific proctocolitis in northeastern Scotland: a community study. Gastroenterology 1983, 85:1-11.
38. Stonnington C.M., Phillips S.F., Zinsmeister A.R., Melton L.J. Prognosis of chronic ulcerative colitis in a community. Gut 1987, 28:1261-1266.
39. Bresci G., Parisi G., Mazzoni A., et al. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis 2007, 39:430-434.
40. Hepburn A.L., Mason J.C., Davies K.A. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis. Rheumatology (Oxford) 2004, 43:547-554.
41. Hanai H., Watanabe F., Takeuchi K., et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003, 1:28-35.